{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:25:05Z","timestamp":1777890305584,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Rare Tumors"],"published-print":{"date-parts":[[2013,5,2]]},"abstract":"<jats:p>A 57-year-old woman presented to her ophthalmologist because of rapid deterioration in vision. Dilated funduscopic examination of the right eye showed an elevated, yellow-orange choroidal mass temporal to the fovea; a complete retinal detachment was present in the left eye. The patient was referred to an oncologist. Computerized tomography of the brain, thorax, abdomen, and pelvis were obtained. They revealed an 11-mm mass in the right parietal lobe, a 30-mm mass in the left temporal lobe, 23-mm mass in the right kidney, and multiple nodules in both lungs. Supported by published experience with intravitreal bevacizumab for choroidal metastasis, the patient was injected into the vitreous through the pars plana of the left eye. The tumor mass did not show signs of regression and the visual acuity was unchanged. The patient suffered from end-state complications tumor metastasis and expired one month after the invitreal injection.<\/jats:p>","DOI":"10.4081\/rt.2013.e5","type":"journal-article","created":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T10:36:27Z","timestamp":1362393387000},"page":"18-20","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Progression of choroidal metastasis of ovarian serous cystoadenocarcinoma after intravitreal bevacizumab treatment"],"prefix":"10.1177","volume":"5","author":[{"given":"Irene C.","family":"Kuo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben H.","family":"Sambuelli","sequence":"additional","affiliation":[{"name":"Pathology Department, Cornea and Anterior Segment Research, Catholic University of Cordoba, School of Medicine, Cordoba, Argentina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bono","sequence":"additional","affiliation":[{"name":"Ophthalmology Service, Cordoba Hospital, Cordoba, Argentina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Instituto de la Visi\u00f3n Cerro de las Rosas, Sanatorio Allende, C\u00f3rdoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E.","family":"Reviglio","sequence":"additional","affiliation":[{"name":"Pathology Department, Cornea and Anterior Segment Research, Catholic University of Cordoba, School of Medicine, Cordoba, Argentina;"},{"name":"Ophthalmology Service, Cordoba Hospital, Cordoba, Argentina;"},{"name":"Instituto de la Visi\u00f3n Cerro de las Rosas, Sanatorio Allende, C\u00f3rdoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,5,1]]},"reference":[{"key":"bibr1-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2008.2"},{"key":"bibr2-rt.2013.e5","unstructured":"BurgerR FlemingG Phase III randomized study of carboplatin and paclitaxel versus carboplatin, paclitaxel, and concurrent bevacizumab without versus with extended bevacizumab in patients with stage III or IV ovarian epithelial or primary peritoneal cancer (GOG-0218) Nation Cancer Institute, trial NCT00262847Available from; http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00262847 Accessed: September 2012"},{"key":"bibr3-rt.2013.e5","unstructured":"WalkerJ A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma NCI-supplied agent(s): Bevacizumab (NSC #704865, IND #7921 National Cancer Institue, Trial NCT00951496Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00951496 Accessed: December 2012"},{"key":"bibr4-rt.2013.e5","volume-title":"Racial\/ethnic patterns of cancer in the United States 1988\u20131992","author":"Miller BA","year":"1996"},{"key":"bibr5-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-010-0054-2"},{"key":"bibr6-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.5.8506"},{"key":"bibr7-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1318"},{"key":"bibr8-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.24.13203"},{"key":"bibr9-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1593"},{"key":"bibr10-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.17.1459"},{"key":"bibr11-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq368"},{"key":"bibr12-rt.2013.e5","unstructured":"BurgerRA BradyML BookmanMAPhase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): a gynecologic oncology group study J Clin Oncol 201028 (suppl)abstract LBA1. Available from: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52788"},{"key":"bibr13-rt.2013.e5","first-page":"104","volume-title":"Devita, Hellman & Rosenberg's Cancer: principles & practice of oncology","author":"Kerbel S","year":"2008"},{"key":"bibr14-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200409115"},{"key":"bibr15-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.06.031"},{"key":"bibr16-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1101\/gad.242002"},{"key":"bibr17-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.19.7282-7291.2000"},{"key":"bibr18-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.01.022"},{"key":"bibr19-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000136345.81719.37"},{"key":"bibr20-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2008.02.009"},{"key":"bibr21-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.08.040"},{"key":"bibr22-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6275"},{"key":"bibr23-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-010-0892-z"},{"key":"bibr24-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2009.23.2.127"},{"key":"bibr25-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e09-07-0591"},{"key":"bibr26-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.088"},{"key":"bibr27-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1520"},{"key":"bibr28-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.08.011"},{"key":"bibr29-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31815a7b69"},{"key":"bibr30-rt.2013.e5","first-page":"95","volume":"2005","author":"Miller KD","year":"2005","journal-title":"EXS"},{"key":"bibr31-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950130106"},{"key":"bibr32-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013172910858"},{"key":"bibr33-rt.2013.e5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4126"}],"container-title":["Rare Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4081\/rt.2013.e5","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4081\/rt.2013.e5","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4081\/rt.2013.e5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:14Z","timestamp":1777613714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4081\/rt.2013.e5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,5,2]]}},"alternative-id":["10.4081\/rt.2013.e5"],"URL":"https:\/\/doi.org\/10.4081\/rt.2013.e5","relation":{},"ISSN":["2036-3613","2036-3613"],"issn-type":[{"value":"2036-3613","type":"print"},{"value":"2036-3613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,1]]}}}